The Differential Impact of Proton Beam Irradiation Versus Conventional Radiation on Organs-at-risk in Stage II-III Breast Cancer Patients
| Status: | Recruiting |
|---|---|
| Conditions: | Breast Cancer |
| Therapuetic Areas: | Oncology |
| Healthy: | No |
| Age Range: | 21 - Any |
| Updated: | 11/11/2018 |
| Start Date: | October 26, 2017 |
| End Date: | July 2027 |
| Contact: | Rachel Jimenez, MD |
| Email: | RBJIMENEZ@PARTNERS.org |
| Phone: | 617-726-7559 |
The objective of the study is to serve as a correlative study for patients enrolled on the
RadCOMP trial (NCT02603341), a randomized phase III study of stage II and III breast cancer
patients treated with either conventional photon radiation or proton beam radiation
RadCOMP trial (NCT02603341), a randomized phase III study of stage II and III breast cancer
patients treated with either conventional photon radiation or proton beam radiation
Inclusion Criteria:
- Eligible for and scheduled to receive radiation therapy on Radiation Therapy Oncology
Group (RTOG) Trial 3510 (Pragmatic Phase III Randomized Trial of Proton vs Photon
Therapy for Patients with Non-Metastatic Breast Cancer Receiving Comprehensive Nodal
Radiation: A Radiotherapy Comparative Effectiveness (RADCOMP) Consortium Trial).
(NCT02603341)
- Ability to understand and the willingness to sign a study-specific written informed
consent document
Exclusion Criteria:
- There are no exclusion criteria.
We found this trial at
1
site
185 Cambridge Street
Boston, Massachusetts 02114
Boston, Massachusetts 02114
617-724-5200
Phone: 617-726-7559
Click here to add this to my saved trials
